Good news, eaters and readers — over the past five weeks, 20 new restaurants have opened in our area, so there's no reason to ...

The special game kicked off with the opening of Gilly’s, a new sports bar inside the arena inspired by Nick Gilbert. Nick, ...

Sumrall, MD The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform ...

"Nobody ever knew what happened to them. They just disappeared." Jamie Smallboy is the founder of the Red Ribbon Skirt Project. (Submitted by Jamie Smallboy ) Smallboy says feeling the spirit of ...

The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults and children. The drug, developed by SpringWorks Therapeutics ...

Gomekli is the second ever FDA-approved treatment for rare tumor disease, NF1-PN and the first to be approved for both adult and pediatric patients. The FDA has approved SpringWorks Therapeutics’ ...

What is neurofibromatosis type 1 (NF1)? Neurofibromatosis type 1 (NF1) is a genetic condition where tumors (mostly benign) grow on skin, nerves, and bones. It is also known as von Recklinghausen ...

Neurofibromatosis type 2 (NF2-related schwannomatosis) is a genetic condition that causes tumors to grow around nerves, often in the brain and spine. These tumors are usually non-cancerous (benign).

Feb. 12, 2025 – The FDA has approved a new pill for a rare genetic disorder called neurofibromatosis type 1 (NF1). It is for adults and children ages 2 and older who have nerve tumors ...

The disease, neurofibromatosis type 1 (NF1), is technically not cancer as the tumors that form are benign. But NF1 can lead to cancers. Even if a patient’s tumors aren’t cancerous, they are ...

“The NF1-PN patient community has a great need for more treatment options. With today’s approval, we are honored to serve both adults and children with NF1-PN and provide them with a therapy ...